Abstract
Twelve patients with vertebral fracture osteoporosis were recruited into a trial of treatment with hPTH 1–34 by daily injection for 1 year combined (from the 5th month) with an anti-resorptive agent (oestrogen, n=9; nandrolone, n=3). Treatment outcomes were monitored by biochemical and radiotracer measurements together with histomorphometry of transiliac biopsies before and at the end of treatment following double in vivo pre-labelling with demethylchlortetracyc-line. Indices of whole body bone formation, obtained from the analysis of85Sr data, showed substantial increases (P<0.005) for all three indices measured) while biochemical (hydroxyproline) and kinetic measurements of bone resorption showed modest and equivocal changes only. As a result calcium balance improved. Gastrointestinal calcium absorption showed a tendency to improve, while urine calcium decreased; but these changes were statistically not significant except for radiocalcium absorption in the oestrogen treated subgroup. Histomorphometry revealed substantial increases in cancellous bone volume as reported previously with hPTH 1–34 given alone. However, iliac (as distinct from whole body) indices related to bone formation and resorption appeared to have returned towards pre-treatment values by the time of the second biopsy under the influence of the anti-resorptive agent given with the hPTH 1–34. It is confirmed that hPTH 1–34 therapy can increase iliac cancellous bone mass (as well as spinal cancellous bone mass as reported earlier) without a long-term increment in whole body bone resorption, providing the hPTH is combined with an anti-resorptive agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reeve J, Meunier PJ, Parsons JA et al. The anabolic effect of human parathyroid hormone fragment (hPTH 1–34) therapy on trabecular bone in involutional osteoporosis: Report of a multicentre trial. Br Med J 1980; 280: 1340–4.
Hesp R, Hulme P, Williams D, Reeve J. The relationship between changes in femoral bone density and calcium balance in patients with involutional osteoporosis treated with human parathyroid hormone fragment (hPTH 1–34). Metab Bone Dis Rel Res 1981; 2: 331–4.
Neer RM, Slovik D, Doppelt S et al. The use of parathyroid hormone plus 1,25 dihydroxyvitamin D to increase trabecular bone in oesteoporotic men and postmenopausal women. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen: Osteopress ApS 1987: 829–35.
Reeve J. Davies UM, Hesp R, McNally E, Katz D. Human parathyroid peptide treatment of osteoporosis substantially increases spinal trabecular bone. Br Med J 1990; 301: 314–18 and 477.
Reeve J, Arlot ME, Price TR et al. Periodic courses of human 1–34 parathyroid peptide alternating with calcitriol paradoxically reduce bone remodelling in spinal osteoporosis. Eur J Clin Invest 1987; 17: 421–8.
Rittinghaus EF, Busch U, Prokop M, Delling G, Hesch RD. Increase of vertebral density in osteoporotic patients: Combination-therapy with 1–38 hPTH and cyclic addition of calcitonin nasal spray. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Copenhagen: Oestopress ApS 1987: 888–91.
Hodsman AB, Fraher LJ. Biochemical responses to sequential human parathyroid hormone (1–38) and calcitonin in osteoporotic patients. Bone Miner 1990; 9: 137–52.
Reeve J, Green JR, Hesp R, Hulme P. Rates of new bone formation in patients with crush fracture osteoporosis. Clin Sci 1982; 63: 153–60.
Wootton R, Reeve J. The relative merits of various techniques for measuring radiocalcium absorption. Clin Sci 1980; 58: 287–93.
Reeve J, Arlot ME, Chavassieux PM et al. The assessment of bone formation and bone resorption in osteoporosis: a comparison between tetracycline-based iliac histomorphometry and whole body85Sr kinetics. J Bone Miner Res 1987; 2: 479–89.
Reeve J, Wootton R, Hesp R. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as tracer for bone calcium. Calcif Tissue Res 1976; 20: 121–35.
Burkinshaw L, Marshall DH, Oxby CB, Spiers FW, Nordin BEC, Young MM. Bone turnover model based on a continuously expanding exchangeable calcium pool. Nature 1969; 222: 146–8.
Tellez M, Reeve J, Royston JP, Veall N, Wootton R. The reproducibility of double isotope deconvolution measurements of radiocalcium absorption. Clin Sci 1980; 59: 169–72.
Meunier PJ, Courpron P, Edouard C et al. Bone histomorphometry in osteoporotic states. In: Barzel US, ed. Osteoporosis II, New York: Grune & Stratton 1979: 27–47.
Arlot ME, Edouard C, Meunier PJ, Neer RM, Reeve J. Impaired osteoblast function in osteoporosis. Comparison between calcium balance and dynamic histomorphometry. Br Med J 1984; 289: 517–20.
Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 1987; 2: 595–610.
Deacon AC, Hulme P, Hesp R et al. Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta 1987; 166: 297–306.
Brown BL, Albano JDM, Ekins RP, Sgherzi AM, Tampion W. A simple sensitive saturation assay method for the measurement of adenosine 3′5′-cyclic monophosphate. Biochem J 1971; 121: 561–2.
Zanelli JM, Rafferty B, Stevenson RW, Parsons JA. An homologous and sensitive radioimmunoassay for the synthetic aminoterminal (1–34) fragment of human parathyroid hormone: application to the clearance of this peptide administered in vivo. J Immunoassay 1980; 1: 289–308.
Desplan C, Julienne A, Moukhtar MS, Milhaud G. Sensitive assay for biologically active fragment of human parathyroid hormone. Lancet 1977; ii: 198–9.
Vogel M, Hesch R-D, Delling G. Morphologische Untersuchung der Beckenkammspongiosa bei Patienten mit Osteoporose unter einer Kombinationstherapie mit pulsatiler Gabe von Parathormon (1–38 hPTH) und sequentieller Verabreichung von Calcitonin-Nasenspray. Med Klin 1990; 85: 82–6.
Reeve J, Wootton R, Hesp R. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium-85 as tracer for bone calcium. Calcif Tissue Res 1976; 20: 121–35.
Logue FC, Fraser WD, O'Reilly DStJ, Beastall GH. The circadian rhythm of intact parathyroid hormone (1–84) and nephrogenous cyclic adenosine monophosphate in normal men. J. Endocrinol 1989; 121: R1-R3.
Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-lα-hyd-roxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988; 42: 77–86.
Chesnut CH III, Ivey JL, Gruber HE et al, Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanism of action. Metabolism 1983; 32: 571–80.
Guesens P, Dequeker J. Long-term effect of nandrolone decanoate, lα-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone Miner 1986; 1: 347–57.
Audran M, Basle M-F, Defontaine A et al. Transient hypoparathyroidism induced by synthetic hPTH 1–34 treatment. J Clin Endocrinol Metab 1987; 64: 937–43.
Lindsay R. Sex steroids in the pathogenesis and formation of osteoporosis. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, diagnosis and management. New York, Raven Press 1988; 333–58.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reeve, J., Bradbeer, J.N., Arlot, M. et al. hPTH 1–34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporosis Int 1, 162–170 (1991). https://doi.org/10.1007/BF01625448
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01625448